PMID- 37439770
OWN - NLM
STAT- MEDLINE
DCOM- 20230721
LR  - 20230905
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 19
IP  - 2
DP  - 2023 Aug 1
TI  - Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in 
      pregnant women.
PG  - 2228670
LID - 10.1080/21645515.2023.2228670 [doi]
LID - 2228670
AB  - This open-labeled non-inferiority trial evaluated immunogenicity and 
      reactogenicity of heterologous and homologous COVID-19 vaccination schedules in 
      pregnant Thai women. 18-45-year-old pregnant women with no history of COVID-19 
      infection or vaccination and a gestational age of >/=12 weeks were randomized 1:1:1 
      into three two-dose primary series scheduled 4 weeks apart: BNT162b2-BNT162b2 
      (Group 1), ChAdOx1-BNT162b2 (Group 2), and CoronaVac-BNT162b2 (Group 3). Serum 
      antibody responses, maternal and cord blood antibody levels at delivery, and 
      adverse events (AEs) following vaccination until delivery were assessed. The 124 
      enrolled participants had a median age of 31 (interquartile range [IQR] 
      26.0-35.5) years and gestational age of 23.5 (IQR 18.0-30.0) weeks. No 
      significant difference in anti-receptor binding domain (RBD) IgG were observed 
      across arms at 2 weeks after the second dose. Neutralizing antibody geometric 
      mean titers against the ancestral Wuhan strain were highest in Group 3 (258.22, 
      95% CI [187.53, 355.56]), followed by Groups 1 (187.47, 95% CI [135.15, 260.03]) 
      and 2 (166.63, 95% CI [124.60, 222.84]). Cord blood anti-RBD IgG was correlated 
      with, and equal to or higher than, maternal levels at delivery (r = 0.719, 
      P < .001) and inversely correlated with elapsed time after the second vaccination 
      (r = -0.366, P < .001). No significant difference in cord blood antibody levels 
      between groups were observed. Local and systemic AEs were mild-to-moderate and 
      more frequent in Group 2. Heterologous schedules of CoronaVac-BNT162b2 or 
      ChAdOx1-BNT162b2 induced immunogenicity on-par with BNT162b2-BNT162b2 and may be 
      considered as alternative schedules for primary series in pregnant women in 
      mRNA-limited vaccine settings.
FAU - Chayachinda, Chenchit
AU  - Chayachinda C
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok, Thailand.
FAU - Watananirun, Kanokwaroon
AU  - Watananirun K
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok, Thailand.
FAU - Phatihattakorn, Chayawat
AU  - Phatihattakorn C
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok, Thailand.
FAU - Anuwutnavin, Sanitra
AU  - Anuwutnavin S
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, 
      Mahidol University, Bangkok, Thailand.
FAU - Niyomnaitham, Suvimol
AU  - Niyomnaitham S
AD  - Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
AD  - Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Phongsamart, Wanatpreeya
AU  - Phongsamart W
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Lapphra, Keswadee
AU  - Lapphra K
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Wittawatmongkol, Orasri
AU  - Wittawatmongkol O
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Rungmaitree, Supattra
AU  - Rungmaitree S
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Jansarikit, Laddawan
AU  - Jansarikit L
AD  - Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Boonnak, Kobporn
AU  - Boonnak K
AD  - Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Wongprompitak, Patimaporn
AU  - Wongprompitak P
AD  - Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Senawong, Sansnee
AU  - Senawong S
AD  - Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Upadhya, Avishek
AU  - Upadhya A
AD  - Department of Sciences, Mahidol University International College, Salaya, Nakhon 
      Pathom, Thailand.
FAU - Toh, Zheng Quan
AU  - Toh ZQ
AD  - Infection and Immunity, Murdoch Children's Research Institute, Parkville, 
      Victoria, Australia.
AD  - Department of Pediatrics, The University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Licciardi, Paul V
AU  - Licciardi PV
AD  - Infection and Immunity, Murdoch Children's Research Institute, Parkville, 
      Victoria, Australia.
AD  - Department of Pediatrics, The University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Chokephaibulkit, Kulkanya
AU  - Chokephaibulkit K
AUID- ORCID: 0000-0002-0140-4600
AD  - Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj 
      Hospital, Mahidol University, Bangkok, Thailand.
AD  - Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol 
      University, Bangkok, Thailand.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20230713
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Antibodies, Viral)
RN  - 0 (BNT162 Vaccine)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Immunoglobulin G)
RN  - 0 (sinovac COVID-19 vaccine)
SB  - IM
CIN - Hum Vaccin Immunother. 2023 Aug 1;19(2):2245694. PMID: 37650290
MH  - Adolescent
MH  - Adult
MH  - Female
MH  - Humans
MH  - Infant
MH  - Middle Aged
MH  - Pregnancy
MH  - Young Adult
MH  - Antibodies, Viral
MH  - BNT162 Vaccine
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - Immunogenicity, Vaccine
MH  - Immunoglobulin G
MH  - *Pregnancy Complications, Infectious/prevention & control
MH  - Pregnant Women
MH  - Vaccination
PMC - PMC10406153
OTO - NOTNLM
OT  - BNT162b2
OT  - ChAdOx1
OT  - CoronaVac
OT  - Heterologous schedules
OT  - Homologous schedules
OT  - Thailand
COIS- No potential conflicts of interest were reported by the authors.
EDAT- 2023/07/13 12:31
MHDA- 2023/07/21 06:44
PMCR- 2023/07/13
CRDT- 2023/07/13 10:43
PHST- 2023/07/21 06:44 [medline]
PHST- 2023/07/13 12:31 [pubmed]
PHST- 2023/07/13 10:43 [entrez]
PHST- 2023/07/13 00:00 [pmc-release]
AID - 2228670 [pii]
AID - 10.1080/21645515.2023.2228670 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2023 Aug 1;19(2):2228670. doi: 
      10.1080/21645515.2023.2228670. Epub 2023 Jul 13.